Lilly, Bristol-Myers approved to market wider Erbitux use
Eli Lilly and Co. and Bristol-Myers Squibb Co. won U.S. approval to expand marketing of the cancer drug Erbitux for late-stage head and neck tumors.
Health Care & Life Sciences
Articles
Glucose monitor deal helps Roche catch up
Roche Diagnostics will partner with a San Diego firm to incorporate its continuous glucose monitoring sensor with a wireless handheld device Roche is developing to help diabetics test their blood sugar and track their glucose levels throughout the day.
Drug shortages hit Lilly, Endocyte
The nation’s shortage of certain drugs is threatening to affect research trials being conducted by Eli Lilly and Co. and Endocyte Inc.
Carmel free clinic drawing jobless professionals
Trinity Free Clinic in Carmel began in 2000 to serve a growing Hispanic immigrant population. Since the latest recession, so many people—including unemployed professionals—have found their way to the clinic that the portion of white patients has grown from one-third in 2008 to 47 percent last year.
Lilly hid Zyprexa’s diabetes risks, family’s lawyer argues
Eli Lilly and Co. hid the diabetes risks of Zyprexa to protect sales, a lawyer for the family of a 20-year-old patient who died while taking the medicine told a jury in the first case to go to trial over the drug. The attorney asked jurors to award the family $40 million in compensatory damages.
Lilly loses British Supreme Court ruling over gene patent
The British Supreme Court ruled in favor of Human Genome Sciences Inc. in its dispute with Eli Lilly and Co. over the validity of a patent for a gene sequence that could be used to treat people with immune diseases.
Cardinal Fitness closing six area fitness centers
Health-club chain plans to keep six local locations open, but refer members of closed locations to LA Fitness.
IU med school gets $9M for Alzheimer’s center
The grant is the fifth consecutive five-year grant the Alzheimer Disease Center has received from NIH to support research to understand the causes and potential treatments for Alzheimer’s and other forms of dementia.
Indiana officials blast feds for ‘over-regulation’ on reform
Michael Gargano, secretary of the Indiana Family and Social Services Administration, blasted the rules for both “glaring omissions” as well as creating new and unfunded “mandates” not included in the 2010 health reform law
Q&A
As an Eli Lilly and Co. lobbyist in Washington, D.C., Jay Bonitt is hoping the Congressional “super committee” charged with trimming the federal budget doesn’t turn to the Medicare prescription drug program, known as Part D, to do so. Bonitt, Lilly's vice president of federal affairs, said the program is under budget and helps spur drugmakers to further innovation.
Not following directions could bite local hospital
Indianapolis-based Westview Hospital might be on the hook for $160,000 because its advisers used a fax machine to tell Lehman Brothers it was canceling a financial agreement.
Insurer Humana’s quarterly profit climbs 13 percent
Humana Inc. raised its 2011 earnings forecast, following the lead set by other big insurers, including competitor WellPoint Inc.
Ortho firms pull back on doc payments
The number of payments in excess of $1 million didn’t change substantially from year to year, but orthopedic companies sharply cut their fees to surgeons who received the smallest amounts.
Kaiser: Lack of competition endemic
In a new study, Indiana ranked as the 19th least-competitive state for individual health insurance and the 27th least-competitive for small-employer health insurance.
State’s first Alzheimer’s-only nursing home to open
American Senior Communities says Auguste's Cottage at Harrison Terrace on the east side of Indianapolis already has 90 residents.
Lilly wins European approval for new use of Alimta
Indianapolis-based drugmaker can now market lung cancer drug as a continuation maintenance therapy, potentially boosting sales after recent loss of patent on bestseller Zyprexa.
Zyprexa era comes to an end for Lilly
On Oct. 24, the U.S. Food and Drug Administration approved the first generic versions of Eli Lilly and Co.’s best-seller, ending 15 years of highly lucrative sales.
Startup aims to mend doctors’ social media woes
RepuChek software tracks, analyzes what’s being said about doctors on the Internet.
Lilly fights view that fate hinges on Alzheimer’s drug
Analysts have eyes on trial data for drug that could be a game-changer for the company.
Dow Agro improves quarterly revenue, profit
Indianapolis-based Dow AgroSciences on Thursday reported record third-quarter sales of $1.2 billion, up 27 percent from the same period a year ago.